deflazacort has been researched along with oligonucleotides in 2 studies
| Studies (deflazacort) | Trials (deflazacort) | Recent Studies (post-2010) (deflazacort) | Studies (oligonucleotides) | Trials (oligonucleotides) | Recent Studies (post-2010) (oligonucleotides) |
|---|---|---|---|---|---|
| 452 | 99 | 115 | 23,128 | 245 | 7,331 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agboola, F; Fluetsch, N; Lin, GA; Pearson, SD; Rind, DM; Walton, SM | 1 |
| Brandsema, JF | 1 |
2 review(s) available for deflazacort and oligonucleotides
| Article | Year |
|---|---|
The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy.
Topics: Cost-Benefit Analysis; Dystrophin; Exons; Humans; Immunosuppressive Agents; Models, Economic; Morpholinos; Muscular Dystrophy, Duchenne; Oligonucleotides; Oligonucleotides, Antisense; Prednisone; Pregnenediones; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Evaluating a Stone of Hope: ICER's 2019 Review of Treatments for Duchenne Muscular Dystrophy.
Topics: Cost-Benefit Analysis; Humans; Insurance Coverage; Insurance, Pharmaceutical Services; Morpholinos; Muscular Dystrophy, Duchenne; Oligonucleotides; Pregnenediones; United States; United States Food and Drug Administration | 2020 |